# A Study to Evaluate the Efficacy and Safety of Mizoribine in the Treatment of Refractory Nephrotic Syndrome

> **NCT02257697** · PHASE3 · COMPLETED · sponsor: **Asahi Kasei Therapeutics Corporation** · enrollment: 239 (actual)

## Conditions studied

- Nephrotic Syndrome

## Interventions

- **DRUG:** Mizoribine (MZR)
- **DRUG:** Cyclophosphamide (CTX)

## Key facts

- **NCT ID:** NCT02257697
- **Lead sponsor:** Asahi Kasei Therapeutics Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-11
- **Primary completion:** 2018-11
- **Final completion:** 2018-11
- **Target enrollment:** 239 (ACTUAL)
- **Last updated:** 2019-01-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02257697

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02257697, "A Study to Evaluate the Efficacy and Safety of Mizoribine in the Treatment of Refractory Nephrotic Syndrome". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02257697. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*